Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide

Anne-Claire Groo,1 Nada Matougui,2 Anita Umerska,2,3 Patrick Saulnier2,4 1Normandie Univ, UNICAEN, CERMN - EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE, Caen, France; 2Micro & Nanomédecines Translationelles-MINT, UNIV Angers, INSERM U1066, CNRS UMR 6021, UBL Universite Bretagne Loi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Groo AC, Matougui N, Umerska A, Saulnier P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	nanoparticles nanomedicine antibacterial AMP methicillin-resistant Staphylococcus aureus infection Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/64fa5727ae2c4be7b9fec604414b344e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:64fa5727ae2c4be7b9fec604414b344e
record_format	dspace
spelling	oai:doaj.org-article:64fa5727ae2c4be7b9fec604414b344e2021-12-02T02:20:01ZReverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide1178-2013https://doaj.org/article/64fa5727ae2c4be7b9fec604414b344e2018-11-01T00:00:00Zhttps://www.dovepress.com/reverse-micelle-lipid-nanocapsules-a-novel-strategy-for-drug-delivery--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Anne-Claire Groo,1 Nada Matougui,2 Anita Umerska,2,3 Patrick Saulnier2,4 1Normandie Univ, UNICAEN, CERMN - EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE, Caen, France; 2Micro & Nanomédecines Translationelles-MINT, UNIV Angers, INSERM U1066, CNRS UMR 6021, UBL Universite Bretagne Loire, Angers, France; 3Université de Lorraine, CITHEFOR, Nancy, France; 4Angers University Hospital, Angers, France Introduction: Resistance to traditional antibiotics is an increasingly serious problem. Antimicrobial peptides (AMPs) have emerged as a new therapeutic class with great potential against infectious diseases, as they are less prone to induce resistance. Nanotechnology-based delivery strategies can improve the efficiency and stability of AMPs, particularly against proteolytic degradation. Lipid nanocapsules (LNCs) are a new generation of biomimetic nanocarriers and were used in this study to deliver peptides.Methods: AMP-loaded reverse micelles (RM) were developed and incorporated into LNCs by the phase inversion process and the antimicrobial activity of the AMPs-loaded LNC was evaluated by the minimum inhibitory concentration method. We studied the activity of AMP solutions and AMP-loaded LNCs against Gram-positive and Gram-negative bacterial strains and then evaluated the encapsulation of a new cationic AMP called AP138. Finally, we analyzed the effect of enzymatic attack on AP138 and AP138-RM-LNCs after incubation with trypsin.Results: AP138 was efficiently encapsulated in the LNCs (encapsulation efficiency = 97.8% at a drug loading of 0.151%), resulting in protection against degradation by proteases and the preservation of antimicrobial activity against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus.Conclusion: This study shows that RM-LNCs are an excellent candidate system to deliver AMPs. Keywords: nanoparticles, nanomedicine, antibacterial, AMP, methicillin-resistant Staphylococcus aureus, infectionGroo ACMatougui NUmerska ASaulnier PDove Medical PressarticlenanoparticlesnanomedicineantibacterialAMPmethicillin-resistant Staphylococcus aureusinfectionMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 7565-7574 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	nanoparticles nanomedicine antibacterial AMP methicillin-resistant Staphylococcus aureus infection Medicine (General) R5-920
spellingShingle	nanoparticles nanomedicine antibacterial AMP methicillin-resistant Staphylococcus aureus infection Medicine (General) R5-920 Groo AC Matougui N Umerska A Saulnier P Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide
description	Anne-Claire Groo,1 Nada Matougui,2 Anita Umerska,2,3 Patrick Saulnier2,4 1Normandie Univ, UNICAEN, CERMN - EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE, Caen, France; 2Micro & Nanomédecines Translationelles-MINT, UNIV Angers, INSERM U1066, CNRS UMR 6021, UBL Universite Bretagne Loire, Angers, France; 3Université de Lorraine, CITHEFOR, Nancy, France; 4Angers University Hospital, Angers, France Introduction: Resistance to traditional antibiotics is an increasingly serious problem. Antimicrobial peptides (AMPs) have emerged as a new therapeutic class with great potential against infectious diseases, as they are less prone to induce resistance. Nanotechnology-based delivery strategies can improve the efficiency and stability of AMPs, particularly against proteolytic degradation. Lipid nanocapsules (LNCs) are a new generation of biomimetic nanocarriers and were used in this study to deliver peptides.Methods: AMP-loaded reverse micelles (RM) were developed and incorporated into LNCs by the phase inversion process and the antimicrobial activity of the AMPs-loaded LNC was evaluated by the minimum inhibitory concentration method. We studied the activity of AMP solutions and AMP-loaded LNCs against Gram-positive and Gram-negative bacterial strains and then evaluated the encapsulation of a new cationic AMP called AP138. Finally, we analyzed the effect of enzymatic attack on AP138 and AP138-RM-LNCs after incubation with trypsin.Results: AP138 was efficiently encapsulated in the LNCs (encapsulation efficiency = 97.8% at a drug loading of 0.151%), resulting in protection against degradation by proteases and the preservation of antimicrobial activity against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus.Conclusion: This study shows that RM-LNCs are an excellent candidate system to deliver AMPs. Keywords: nanoparticles, nanomedicine, antibacterial, AMP, methicillin-resistant Staphylococcus aureus, infection
format	article
author	Groo AC Matougui N Umerska A Saulnier P
author_facet	Groo AC Matougui N Umerska A Saulnier P
author_sort	Groo AC
title	Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide
title_short	Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide
title_full	Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide
title_fullStr	Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide
title_full_unstemmed	Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide
title_sort	reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate ap138 antimicrobial peptide
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/64fa5727ae2c4be7b9fec604414b344e
work_keys_str_mv	AT grooac reversemicellelipidnanocapsulesanovelstrategyfordrugdeliveryoftheplectasinderivateap138antimicrobialpeptide AT matouguin reversemicellelipidnanocapsulesanovelstrategyfordrugdeliveryoftheplectasinderivateap138antimicrobialpeptide AT umerskaa reversemicellelipidnanocapsulesanovelstrategyfordrugdeliveryoftheplectasinderivateap138antimicrobialpeptide AT saulnierp reversemicellelipidnanocapsulesanovelstrategyfordrugdeliveryoftheplectasinderivateap138antimicrobialpeptide
_version_	1718402530592948224

Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide

Ejemplares similares